New drugs in acute myeloid leukemia

Por Kadia, T. M., Ravandi, F., Cortes, J., Kantarjian, H.
Publicado no Ann Oncol (2016)

A Phase I Study of a Combination of anti-CD19 and anti-CD22 Immunotoxins (Combotox) in Adult Patients with Refractory B-Lineage Acute Lymphoblastic Leukaemia

Por Schindler, J., Gajavelli, S., Ravandi, F., Shen, Y., Parekh, S., Braunchweig, I., Barta, S, Ghetie, V., Vitetta, E., Verma, A.
Publicado em 2011

A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis

Por Quintás-Cardama, A, Tong, W, Kantarjian, H, Thomas, D, Ravandi, F, Kornblau, S, Manshouri, T, Cortes, JE, Garcia-Manero, G, Verstovsek, S
Publicado no Leukemia (2008)

A phase Ib study of vosaroxin, an anticancer quinolone derivative, in patients with relapsed or refractory acute leukemia

Por Lancet, JE, Ravandi, F, Ricklis, RM, Cripe, LD, Kantarjian, HM, Giles, FJ, List, AF, Chen, T, Allen, RS, Fox, JA, Michelson, GC, Karp, JE
Publicado no Leukemia (2011)

Phase 1 and Extension Study of Clofarabine plus Cyclophosphamide in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)

Por Faderl, S, Balakrishnan, K, Thomas, DA, Ravandi, F, Borthakur, G, Burger, J, Ferrajoli, A, Cortes, J, O’Brien, S, Kadia, T, Feliu, J, Plunkett, W, Gandhi, V, Kantarjian, HM
Publicado em 2013

Clinical, pharmacokinetic and pharmacodynamic data for the MEK1/2 inhibitor pimasertib in patients with advanced hematologic malignancies

Por Ravandi, F, Pigneux, A, DeAngelo, D J, Raffoux, E, Delaunay, J, Thomas, X, Kadia, T, Kantarjian, H, Scheuenpflug, J, Zhao, C, Guo, W, Smith, B D
Publicado no Blood Cancer J (2015)

Lack of association of IDH1, IDH2, and DNMT3A mutations with outcome in older patients with AML treated with hypomethylating agents

Por DiNardo, CD, Patel, KP, Garcia-Manero, G, Luthra, R, Pierce, S, Borthakur, G, Jabbour, E, Kadia, T, Pemmaraju, N, Konopleva, M, Faderl, S, Cortes, J, Kantarjian, H, Ravandi, F
Publicado em 2014